New Treatment for Hemophilia B Launched

The launch comes after Idelvion was FDA approved earlier this month
The launch comes after Idelvion was FDA approved earlier this month

CSL Behring announced the launch of Idelvion (coagulation factor IX [recombinant], albumin fusion protein) for the treatment of hemophilia B. This is the first factor IX therapy that allows up to 14-day dosing in select patients aged ≥12 years.

Idelvion was approved earlier this month for use in adults and children with hemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes; on-demand control and prevention of bleeding episodes; and the perioperative management of bleeding.

RELATED: New Hemophilia B Tx Allows Up to 14 Days Between Infusions

Idelvion contains genetically fused recombinant coagulation Factor IX and recombinant albumin. Fusion with recombinant albumin extends the half-life of Factor IX. The 14-day dosing interval was able to maintain high factor activity of >5% at 75 IU/kg.

Idelvion is supplied in 250 IU, 500 IU, 1000 IU, and 2000 IU vial sizes.

For more information call (866) 915-6958 or visit Idelvion.com.

Loading links....